Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET

Angelo Antonini, Ken Kazumata, Andrew Feigin, Francine Mandel, Vijay Dhawan, Claude Margouleff, David Eidelberg

Research output: Contribution to journalArticle

Abstract

The clinical differentiation between typical idiopathic Parkinson's disease (IPD) and atypical parkinsonian disorders (APD) is complicated by the presence of signs and symptoms common to both forms of parkinsonism. Metabolic brain imaging with [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) may be a useful adjunct in differentiating APD from IPD. To explore this possibility, we studied 48 parkinsonian patients suspected as having possible APD because of a deteriorating response to dopaminergic treatment, the development of autonomic dysfunction, or both. A group of 56 patients with likely IPD served as control subjects. We used quantitative FDG/PET to measure regional rates of cerebral glucose use in IPD and APD patients. We used discriminant analysis to categorize IPD and APD patients based on their regional metabolic data. We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p <0.0001). Significant metabolic abnormalities were present in the striatum and the thalamus of 36 of 48 (75%) APD patients. Our findings show that measurements of regional glucose metabolism can be used to discriminate patients with suspected APD from their counterparts with classic UPD. FDG/PET may be a useful adjunct to the clinical examination in the differential diagnosis of parkinsonism.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalMovement Disorders
Volume13
Issue number2
DOIs
Publication statusPublished - 1998

Fingerprint

Fluorodeoxyglucose F18
Parkinsonian Disorders
Positron-Emission Tomography
Differential Diagnosis
Parkinson Disease
Glucose
Discriminant Analysis
Thalamus
Neuroimaging
Signs and Symptoms

Keywords

  • [F]Fluorodeoxyglucose
  • Atypical parkinsonism
  • Multiple system atrophy
  • Parkinson's disease
  • Positron emission tomography

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Antonini, A., Kazumata, K., Feigin, A., Mandel, F., Dhawan, V., Margouleff, C., & Eidelberg, D. (1998). Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Movement Disorders, 13(2), 268-274. https://doi.org/10.1002/mds.870130212

Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. / Antonini, Angelo; Kazumata, Ken; Feigin, Andrew; Mandel, Francine; Dhawan, Vijay; Margouleff, Claude; Eidelberg, David.

In: Movement Disorders, Vol. 13, No. 2, 1998, p. 268-274.

Research output: Contribution to journalArticle

Antonini, A, Kazumata, K, Feigin, A, Mandel, F, Dhawan, V, Margouleff, C & Eidelberg, D 1998, 'Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET', Movement Disorders, vol. 13, no. 2, pp. 268-274. https://doi.org/10.1002/mds.870130212
Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Movement Disorders. 1998;13(2):268-274. https://doi.org/10.1002/mds.870130212
Antonini, Angelo ; Kazumata, Ken ; Feigin, Andrew ; Mandel, Francine ; Dhawan, Vijay ; Margouleff, Claude ; Eidelberg, David. / Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. In: Movement Disorders. 1998 ; Vol. 13, No. 2. pp. 268-274.
@article{77a497f764f24e3e959e8f1813f8d135,
title = "Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET",
abstract = "The clinical differentiation between typical idiopathic Parkinson's disease (IPD) and atypical parkinsonian disorders (APD) is complicated by the presence of signs and symptoms common to both forms of parkinsonism. Metabolic brain imaging with [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) may be a useful adjunct in differentiating APD from IPD. To explore this possibility, we studied 48 parkinsonian patients suspected as having possible APD because of a deteriorating response to dopaminergic treatment, the development of autonomic dysfunction, or both. A group of 56 patients with likely IPD served as control subjects. We used quantitative FDG/PET to measure regional rates of cerebral glucose use in IPD and APD patients. We used discriminant analysis to categorize IPD and APD patients based on their regional metabolic data. We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p <0.0001). Significant metabolic abnormalities were present in the striatum and the thalamus of 36 of 48 (75{\%}) APD patients. Our findings show that measurements of regional glucose metabolism can be used to discriminate patients with suspected APD from their counterparts with classic UPD. FDG/PET may be a useful adjunct to the clinical examination in the differential diagnosis of parkinsonism.",
keywords = "[F]Fluorodeoxyglucose, Atypical parkinsonism, Multiple system atrophy, Parkinson's disease, Positron emission tomography",
author = "Angelo Antonini and Ken Kazumata and Andrew Feigin and Francine Mandel and Vijay Dhawan and Claude Margouleff and David Eidelberg",
year = "1998",
doi = "10.1002/mds.870130212",
language = "English",
volume = "13",
pages = "268--274",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET

AU - Antonini, Angelo

AU - Kazumata, Ken

AU - Feigin, Andrew

AU - Mandel, Francine

AU - Dhawan, Vijay

AU - Margouleff, Claude

AU - Eidelberg, David

PY - 1998

Y1 - 1998

N2 - The clinical differentiation between typical idiopathic Parkinson's disease (IPD) and atypical parkinsonian disorders (APD) is complicated by the presence of signs and symptoms common to both forms of parkinsonism. Metabolic brain imaging with [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) may be a useful adjunct in differentiating APD from IPD. To explore this possibility, we studied 48 parkinsonian patients suspected as having possible APD because of a deteriorating response to dopaminergic treatment, the development of autonomic dysfunction, or both. A group of 56 patients with likely IPD served as control subjects. We used quantitative FDG/PET to measure regional rates of cerebral glucose use in IPD and APD patients. We used discriminant analysis to categorize IPD and APD patients based on their regional metabolic data. We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p <0.0001). Significant metabolic abnormalities were present in the striatum and the thalamus of 36 of 48 (75%) APD patients. Our findings show that measurements of regional glucose metabolism can be used to discriminate patients with suspected APD from their counterparts with classic UPD. FDG/PET may be a useful adjunct to the clinical examination in the differential diagnosis of parkinsonism.

AB - The clinical differentiation between typical idiopathic Parkinson's disease (IPD) and atypical parkinsonian disorders (APD) is complicated by the presence of signs and symptoms common to both forms of parkinsonism. Metabolic brain imaging with [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) may be a useful adjunct in differentiating APD from IPD. To explore this possibility, we studied 48 parkinsonian patients suspected as having possible APD because of a deteriorating response to dopaminergic treatment, the development of autonomic dysfunction, or both. A group of 56 patients with likely IPD served as control subjects. We used quantitative FDG/PET to measure regional rates of cerebral glucose use in IPD and APD patients. We used discriminant analysis to categorize IPD and APD patients based on their regional metabolic data. We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p <0.0001). Significant metabolic abnormalities were present in the striatum and the thalamus of 36 of 48 (75%) APD patients. Our findings show that measurements of regional glucose metabolism can be used to discriminate patients with suspected APD from their counterparts with classic UPD. FDG/PET may be a useful adjunct to the clinical examination in the differential diagnosis of parkinsonism.

KW - [F]Fluorodeoxyglucose

KW - Atypical parkinsonism

KW - Multiple system atrophy

KW - Parkinson's disease

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0031929675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031929675&partnerID=8YFLogxK

U2 - 10.1002/mds.870130212

DO - 10.1002/mds.870130212

M3 - Article

C2 - 9539340

AN - SCOPUS:0031929675

VL - 13

SP - 268

EP - 274

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -